Evaluating the feasibility of health care databases for assessing the safety of switching between originator biologics and biosimilars

Journal of Managed Care and Specialty Pharmacy · Published 2026-07-27 · DOI 10.18553/jmcp.2026.32.8.968

Free full text

Authors (6)

Aaron B. Mendelsohn, Terese A. DeFor, Djeneba Audrey Djibo, Scott M. Myers, Pamala A. Pawloski, Catherine M. Lockhart

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Mendelsohn, A., DeFor, T., Djibo, D., et al. (2026). Evaluating the feasibility of health care databases for assessing the safety of switching between originator biologics and biosimilars. Journal of Managed Care and Specialty Pharmacy. https://doi.org/10.18553/jmcp.2026.32.8.968

Related articles

• Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Principles and practices for successful gene therapy innovative contracting: Insights from a multistakeholder convening · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Timing of health technology assessment in the United States: An evaluation of ICER reviews over 8 years · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Patient experience data in formulary decision-making: Payer-reported perceptions and use · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Evaluating the design and implementation challenges of the Centers for Medicare & Medicaid Services’ Cell and Gene Therapy Access Model · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• US commercial health plan use of corticosteroids in step therapy protocols: Frequency and clinical appropriateness · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Advancing the measurement of caregiver impact: Data collection priorities aligned with caregiver, health technology assessment, and policy stakeholders · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal